English | Español

Boehringer-Ingelheim
Carol Ostrow | Dec 15, 2017

Boehringer Ingelheim collaborations yield vaccine technology, cancer treatments
Ruth de Jauregui | Jun 14, 2017

Boehringer Ingelheim, Eli Lilly to collaborate in trial of empagliflozin for chronic kidney disease
Gene Johnson | Feb 25, 2017

Combination therapy targets lung cancer
Carol Ostrow | Feb 19, 2017

Partnership spurs efforts against COPD
Amanda Rupp | Jun 28, 2016

Boehringer Ingelheim board of managing directors introduces new member
Amanda Rupp | Jun 5, 2016

Boehringer Ingelheim, Inventiva collaborate for idiopathic pulmonary fibrosis treatments
Amanda Rupp | May 31, 2016

Boehringer Ingelheim to increase HIV/AIDS medication access
Amanda Rupp | May 25, 2016

BioMed X, Boehringer Ingelheim partner for psychiatric treatments

Trending
+ Pharmaceuticals
Patient Daily | Jun 30, 2025

PhRMA public affairs senior director on 340B program: 'PBMs took $140 billion in rebates and fees, driving up American medicine costs'
+ Pharmaceuticals
Patient Daily | Jun 25, 2025

Neurosurgeon at the University of California: ‘340B is being exploited for profit, not patient care’
+ Pharmaceuticals
Patient Daily | Jul 1, 2025

PhRMA chief public affairs officer on 340B drug pricing: ‘Lowering drug prices for U.S. patients starts by reining in middlemen’